McKesson Europe AG
XHAM:CLS1
Relative Value
There is not enough data to reliably calculate the relative value of CLS1.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
CLS1 Competitors Multiples
McKesson Europe AG Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
5B EUR | 0.2 | -5.1 | 3.9 | 19.2 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
116.2B USD | 0.3 | 26.8 | 18.9 | 21.3 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
70.3B USD | 0.2 | 43.3 | 15.2 | 19.2 | |
| US |
|
Cencora Inc
NYSE:COR
|
69.8B USD | 0.2 | 43.1 | 15.1 | 19.1 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
52.8B USD | 0.2 | 31.8 | 15.3 | 19.9 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
33.8B AUD | 5.6 | 63.8 | 48.2 | 48.2 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.6B CNY | 0.2 | 11.3 | 15.2 | 15.2 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
63.1B CNY | 1.5 | 17.1 | 13.2 | 13.2 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9.3B USD | 0.7 | 24 | 11.5 | 16 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
65.8B HKD | 0.1 | 8.6 | 1.6 | 2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 5.9 | 89.6 | 59.9 | 61.9 |